文献速递血栓与止血

5B9:一种模拟肝素诱导的血小板减少症抗体的人Fc段抗血小板因子4/肝素单克隆抗体

5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.
PubMed 文献 · J Thromb Haemost · 2017-09-04

本研究开发了首个带人Fc段、可完全模拟人肝素诱导的血小板减少症(HIT)抗体效应的抗血小板因子4(PF4)/肝素嵌合单克隆抗体5B9,并在体外及表达人PF4和FcγRIIA受体的小鼠中验证其致病性,同时通过表位分析提示其识别的PF4区域可能对HIT抗体致病性关键。

要点

  • 5B9是首个带人Fc段、可完全模拟人HIT抗体效应的抗PF4/肝素单克隆抗体。
  • 5B9可诱导FcγRIIA依赖的血小板聚集及单核细胞组织因子mRNA合成。
  • 5B9在表达人PF4和FcγRIIA受体的小鼠中诱导显著血小板减少和凝血酶生成。

核心结论

  • 5B9是首个带人Fc段、可诱导与人HIT抗体相似细胞活化的抗PF4/肝素单克隆抗体。
  • 5B9结合PF4上可能对HIT抗体致病性关键的表位。

研究设计与样本

  • 通过免疫特定转基因小鼠获得嵌合抗PF4/肝素复合物IgG1抗体5B9并进行表征。

主要发现

  • 5B9诱导FcγRIIA依赖的血小板聚集及单核细胞组织因子mRNA合成。
  • 5B9在表达人PF4和FcγRIIA受体的小鼠中诱导显著血小板减少和凝血酶生成。
  • 25份HIT血浆样本中15份抑制5B9与PF4/肝素复合物结合,而25份含非致病性抗PF4/肝素抗体样本中仅3份抑制。
  • 鼠源IgG2b HIT抗体KKO亦抑制5B9与PF4/肝素结合,提示两抗体识别表位邻近。
  • 基于5B9 VH和VL序列的对接分析显示,5B9 Fab与PF4结合分别涉及B和D单体各12个残基,其中7个为既往鉴定的PF4/KKO复合物形成关键残基。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials No humanized monoclonal antibody was available to study heparin-induced thrombocytopenia (HIT). We developed the first anti-platelet factor 4 (PF4)/heparin antibody with a human Fc fragment. This antibody (5B9) fully mimics the effects of human HIT antibodies. 5B9 binds two regions within PF4 that may be critical for the pathogenicity of HIT antibodies. SUMMARY: Background The diagnosis of heparin-induced thrombocytopenia (HIT) is based on clinical and biological criteria, but a standard is lacking for laboratory assays. Moreover, no humanized HIT antibody is available for pathophysiological studies. Objective To characterise 5B9, a chimeric monoclonal antibody, which fully mimics the effects of human HIT antibodies. Methods/Results 5B9, a chimeric anti-platelet factor 4/heparin complexes IgG1 antibody, was obtained after immunizing specific transgenic mice. 5B9 induced heparin FcγRIIA-dependent platelet aggregation and tissue factor mRNA synthesis in monocytes. It also induced significant thrombocytopenia and thrombin generation in mice expressing human PF4 and FcγRIIA receptors. The binding of 5B9 to PF4/H complexes was inhibited by 15 of 25 HIT plasma samples and only three of 25 samples containing non-pathogenic anti-PF4/H antibodies. KKO, a murine IgG2b HIT antibody, also inhibited the binding of 5B9 to PF4/H, suggesting that epitopes recognized by both antibodies are close. A docking analysis based on VH and VL sequences of 5B9 showed that binding of 5B9 Fab to PF4 involved 12 and 12 residues in B and D monomers, respectively, including seven previously identified as critical to the formation of a PF4/KKO complex. Two regions (Asp-7 to Thr-15 and Ala-32 to Thr-38) therefore appeared important for the binding of 5B9 and KKO on PF4 modified by heparin. Conclusions 5B9 is the first anti-PF4/H monoclonal antibody with a human Fc fragment, which induces similar cellular activation as HIT antibodies. Moreover, 5B9 binds epitopes within PF4 that are likely to be critical for the pathogenicity of HIT antibodies.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kizlik-Masson C, Vayne C, McKenzie SE, et al. 5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies. J Thromb Haemost. 2017. PMID: 28771917. doi:10.1111/jth.13786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。